KVUE

Business Context and Reporting Period

Kenvue Inc. (KVUE) is the world's largest pure-play consumer health company, operating in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company operates globally with iconic brands including Tylenol, Neutrogena, Listerine, and Johnson's. This summary covers the fiscal year ended December 28, 2025.

A material development during the period was the announcement of a Proposed Transaction with Kimberly-Clark Corporation (K-C) on November 2, 2025. Under the Merger Agreement, Kenvue shareholders will receive 0.14625 shares of K-C common stock and $3.50 in cash per share. The transaction was approved by shareholders in January 2026 and is expected to close in the second half of 2026, subject to regulatory approvals.

Key Financial Metrics

Segment Performance (Adjusted Operating Income):

• Self Care: $2.11 billion (down 2.9% vs. prior year)
• Skin Health and Beauty: $0.48 billion (down 21.4% vs. prior year)
• Essential Health: $1.18 billion (up 1.2% vs. prior year)

Material Changes vs. Prior Period

Revenue Decline: Net sales decreased 2.1% primarily due to a 2.3% volume decline driven by trade inventory reductions in the U.S. and shipment timing changes in China. Organic sales decreased 2.2%, with volume decreases of 2.3% partially offset by favorable value realization of 0.1%.

Profitability Improvement: Despite lower sales, Net Income increased 42.7% and Operating Income increased 31.1%. This was largely driven by a significant reduction in Impairment Charges, which fell from $578 million in 2024 (primarily related to Dr.Ci:Labo assets) to $23 million in 2025. Additionally, Selling, General, and Administrative (SG&A) expenses decreased 3.8% due to lower separation-related costs and savings from the "Our Vue Forward" restructuring initiative.

Restructuring: Restructuring expenses increased to $290 million in 2025 from $185 million in 2024, driven by higher IT and project-related costs associated with the 2024 Multi-Year Restructuring Initiative.

Guidance, Outlook, and Risks

Outlook and Restructuring: Management continues to focus on the "Our Vue Forward" initiative, having realized annualized pre-tax gross cost savings in excess of $350 million. A new restructuring initiative was approved by the Board on February 17, 2026, targeting approximately $250 million in pre-tax expenses in fiscal 2026 to optimize the operating model and supply chain.

Proposed Transaction: The merger with Kimberly-Clark remains subject to customary closing conditions, including foreign regulatory approvals. The transaction is expected to close in the second half of 2026. Kenvue has suspended its share repurchase program pending the transaction.

Key Risks and Contingencies:

• Acetaminophen Litigation: The company faces ongoing litigation and regulatory scrutiny regarding acetaminophen (Tylenol) and potential links to autism spectrum disorder and ADHD. In September 2025, the FDA initiated a process for label changes, and citizen petitions were filed requesting updates to reflect potential neurodevelopmental risks.
• Phenylephrine (PE) Regulatory Action: The FDA has proposed removing oral phenylephrine from the OTC monograph due to lack of efficacy. This has led to class actions and potential product reformulations or withdrawals.
• Talc Litigation: While J&J indemnifies Kenvue for talc-related liabilities in the U.S. and Canada, Kenvue remains responsible for liabilities related to talc products sold outside these regions. New claims were filed in the UK and Australia in late 2025/early 2026.
• Macroeconomic Factors: The company estimates a gross tariff exposure of approximately $130 million annualized due to U.S. executive orders on imports.

Investor Verification Checklist

• Merger Status: Verify the status of regulatory approvals for the Kimberly-Clark merger and any potential delays or conditions imposed.
• Acetaminophen Impact: Monitor FDA final decisions on acetaminophen labeling and the outcome of pending litigation to assess potential sales impact on the Tylenol brand.
• Skin Health Segment: Review the long-term outlook for the Skin Health and Beauty segment, which saw a 21.4% drop in adjusted operating income and a goodwill impairment test where fair value exceeded carrying value by only 10%.
• Restructuring Execution: Track the execution of the new $250 million restructuring initiative approved in February 2026 and its impact on future cost structures.
• Phenylephrine Reformulation: Assess the timeline and cost associated with reformulating or removing products containing oral phenylephrine following the FDA's proposed order.